Perlin D V, Dymkov I N, Terentiev A V, Perlina A V
Volgograd Regional Center of Urology and Nephrology, Volzhsky, Russia.
Volgograd Regional Center of Urology and Nephrology, Volzhsky, Russia.
Transplant Proc. 2021 May;53(4):1138-1142. doi: 10.1016/j.transproceed.2021.01.025. Epub 2021 Jan 14.
In recent months, the number of kidney transplants from deceased donors has declined significantly. One of the reasons is the possibility of infection of the recipient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Determining the risk of transmission of coronavirus disease 2019 (COVID-19) with a donor organ is very important for developing a kidney transplantation policy during a pandemic.
We present cases of kidney transplantation from COVID-19-positive deceased donors to 2 dialysis patients 49 and 45 years old. One of them was on hemodialysis for 28 months; the other received continuous ambulatory peritoneal dialysis (CAPD). Both patients received only basic immunosuppression, including tacrolimus, methylprednisolone, and mycophenolic acid. No antilymphocyte agents were used for induction therapy.
Cold ischemia time was 22 and 21 hours, respectively. One recipient had delayed graft function with increasing of urine output on day 8; another had immediate function. Both patients had no febrile and no other symptoms of acute respiratory disease during their hospital stay. No abnormalities on the chest x-ray were seen. No serum anti-SARS-CoV-2 IgM and IgG were detected before and during 6 weeks after surgery. Repeated nasopharyngeal swabs real-time reverse transcription polymerase chain reaction (rRT-PCR) were negative during the period. Both recipients were discharged 5 weeks after surgery with serum creatinine levels of 122 and 91 mcmol/L, respectively.
Today we have no evidence of the possibility of transmission of COVID-19 from a SARS-CoV-2 positive donor to a kidney recipient. We also have no reason to suspect kidney damage by COVID-19 in a deceased donor at normal serum creatinine level.
近几个月来,来自已故捐赠者的肾移植数量显著下降。原因之一是受者有可能感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。确定2019冠状病毒病(COVID-19)通过供体器官传播的风险对于制定大流行期间的肾移植政策非常重要。
我们报告了将COVID-19阳性已故捐赠者的肾脏移植给两名分别为49岁和45岁的透析患者的病例。其中一名患者接受血液透析28个月;另一名接受持续性非卧床腹膜透析(CAPD)。两名患者均仅接受基本免疫抑制治疗,包括他克莫司、甲泼尼龙和霉酚酸。诱导治疗未使用抗淋巴细胞药物。
冷缺血时间分别为22小时和21小时。一名受者移植肾功能延迟,术后第8天尿量增加;另一名受者移植肾功能立即恢复。两名患者住院期间均无发热及其他急性呼吸道疾病症状。胸部X线检查未见异常。术后6周内术前及术中均未检测到血清抗SARS-CoV-2 IgM和IgG。在此期间,重复鼻咽拭子实时逆转录聚合酶链反应(rRT-PCR)均为阴性。两名受者均在术后5周出院,血清肌酐水平分别为122和91 μmol/L。
目前我们没有证据表明COVID-19有可能从SARS-CoV-2阳性供体传播给肾移植受者。我们也没有理由怀疑血清肌酐水平正常的已故捐赠者的肾脏受到COVID-侵袭。 19损伤。